You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nonalcoholic steatohepatitis (NASH)

Showing 1 - 25 of 1,040
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Nonalcoholic Steatohepatitis (NASH) Trial in Guangzhou (ZSP1601, Placebo)

Not yet recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • Guangzhou, China
    NanFang Hospital
Jan 10, 2023

Non-Alcoholic Steatohepatitis (NASH) Trial in Fort Myers, Sarasota (Pemvidutide, Placebo)

Recruiting
  • Non-Alcoholic Steatohepatitis (NASH)
  • Fort Myers, Florida
  • +1 more
Aug 10, 2023

Nonalcoholic Steatohepatitis (NASH) Trial in Gent (ORMD-0801 QD, ORMD-0801 BD)

Completed
  • Nonalcoholic Steatohepatitis (NASH)
  • ORMD-0801 QD
  • ORMD-0801 BD
  • Gent, Belgium
    Universitaire Ziekenhuis Gent
Sep 15, 2022

Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial in Hialeah Gardens

Recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • Metabolic Dysfunction-associated Steatohepatitis (MASH)
  • Hialeah Gardens, Florida
    Site #430
Nov 1, 2023

Nonalcoholic Steatohepatitis (NASH) Trial (CS0159 (Linafexor))

Not yet recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • CS0159 (Linafexor)
  • (no location specified)
Nov 14, 2022

Nonalcoholic Steatohepatitis (NASH) Trial (ASC41 2 mg, ASC41 4 mg, Placebo)

Not yet recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • ASC41 2 mg
  • +2 more
  • (no location specified)
Jan 30, 2023

Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD Trial (Efinopegdutide, Semaglutide, Placebo)

Not yet recruiting
  • Non-alcoholic Fatty Liver Disease
  • +4 more
  • (no location specified)
May 17, 2023

Nonalcoholic Steatohepatitis (NASH) Trial in United States (Miricorilant 150 mg, Miricorilant 100 mg)

Recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • Miricorilant 150 mg
  • +2 more
  • Chandler, Arizona
  • +9 more
Oct 27, 2022

Nonalcoholic Steatohepatitis (NASH) Trial in Miami Lakes, Tulsa, Waco (HTD1801, Placebo)

Recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • Miami Lakes, Florida
  • +2 more
Jan 13, 2023

Nonalcoholic Steatohepatitis (NASH) Trial in Taiwan (ADI-PEG20, Placebo)

Not yet recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • Kaohsiung, Taiwan
  • +4 more
Apr 24, 2023

Nonalcoholic Steatohepatitis (NASH) Trial in United States (BOS-580, Placebo)

Active, not recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • Birmingham, Alabama
  • +11 more
Dec 4, 2022

Diabetes, Type 2, NASH - Nonalcoholic Steatohepatitis Trial in Tustin, Jerusalem, Tel Aviv (ORMD-0801 (Insulin) capsule 8 mg BD,

Completed
  • Diabetes Mellitus, Type 2
  • NASH - Nonalcoholic Steatohepatitis
  • ORMD-0801 (Insulin) capsule 8 mg BD
  • Placebo
  • Tustin, California
  • +2 more
Sep 13, 2022

NASH - Nonalcoholic Steatohepatitis Trial in San Francisco (Spironolactone 100mg, Placebo oral capsule)

Recruiting
  • NASH - Nonalcoholic Steatohepatitis
  • Spironolactone 100mg
  • Placebo oral capsule
  • San Francisco, California
    University of California San Francisco
Sep 9, 2022

Nonalcoholic Steatohepatitis (NASH) Trial in United States (Miricorilant, Placebo)

Terminated
Has Results
  • Nonalcoholic Steatohepatitis (NASH)
  • Chandler, Arizona
  • +14 more
Aug 10, 2022

Nonalcoholic Steatohepatitis

Recruiting
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Nonalcoholic Steatohepatitis (NASH)
  • Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
  • Montréal, Quebec, Canada
    Centre Hospitalier de l'Université de Montréal
Nov 11, 2022

Pharmacokinetics of Miricorilant in Presumed Nonalcoholic

Recruiting
  • Nonalcoholic Steatohepatitis (NASH)
  • MRI-PDFF
  • Chandler, Arizona
  • +7 more
Apr 8, 2022

NASH - Nonalcoholic Steatohepatitis Trial in United States (Seladelpar, Placebos)

Terminated
Has Results
  • NASH - Nonalcoholic Steatohepatitis
  • Glendale, Arizona
  • +13 more
Aug 30, 2022

NASH, NAFLD Trial in Hangzhou (GH509, Placebo)

Recruiting
  • NASH
  • NAFLD
  • Hangzhou, Zhejiang, China
    The Affiliated Hospital of Hangzhou Normal University
Mar 26, 2023

Fatty Liver, NAFLD Trial in Kansas City (ELF Test)

Recruiting
  • Fatty Liver
  • NAFLD
  • ELF Test
  • Kansas City, Kansas
    University of Kansas Medical Center
May 6, 2022

Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc) Trial in Tel Aviv (CM-101,

Completed
  • Nonalcoholic Steatohepatitis (NASH)
  • +2 more
  • Tel Aviv, Israel
    Tel Aviv Sourasky Medical Center
Sep 7, 2023

Nonalcoholic Steatohepatitis Trial (Saroglitazar Magnesium 4 mg, Placebo)

Not yet recruiting
  • Nonalcoholic Steatohepatitis
  • Saroglitazar Magnesium 4 mg
  • Placebo
  • (no location specified)
Apr 23, 2022

Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD) Trial in New Zealand, United States (SEL, FIR,

Completed
Has Results
  • Nonalcoholic Steatohepatitis (NASH)
  • Nonalcoholic Fatty Liver Disease (NAFLD)
  • Chandler, Arizona
  • +12 more
Mar 7, 2022

Nonalcoholic Steatohepatitis Trial in Cairo (Heptex, Rice bran)

Completed
  • Nonalcoholic Steatohepatitis
  • Cairo, Egypt
  • +1 more
Apr 18, 2022

Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis Trial in Hangzhou (2mg of ASC41, 4mg of ASC41 (2 tablets of 2

Not yet recruiting
  • Non-alcoholic Fatty Liver Disease
  • Non-alcoholic Steatohepatitis
  • 2mg of ASC41
  • +2 more
  • Hangzhou, Zhejiang, China
    The affiliated Hospital of Hangzhou Normal University
Jul 13, 2022

Nonalcoholic Steatohepatitis (NASH) Trial in United States (LPCN 1144 Formulation A, LPCN 1144 Formulation B, Placebo)

Completed
  • Nonalcoholic Steatohepatitis (NASH)
  • LPCN 1144 Formulation A
  • +2 more
  • El Cajon, California
  • +18 more
Aug 1, 2022